A comprehensive meta-analysis published in a leading medical journal has provided some of the strongest evidence to date for the efficacy of THC-based treatments in managing chronic pain. The analysis, which reviewed data from over 40 randomised controlled trials involving more than 5,000 patients, found consistent and clinically significant pain reduction across multiple conditions.
Key findings
The analysis found that THC-dominant treatments were associated with a 30% or greater reduction in pain scores compared to placebo in patients with neuropathic pain, fibromyalgia, and chronic musculoskeletal conditions. Importantly, the benefits were seen across different formulations and routes of administration.
Cautious interpretation
While the results are encouraging, the authors note important caveats. Side effects, including dizziness, dry mouth, and cognitive effects, were more common with THC-based treatments. Long-term safety data remains limited. And the optimal dosing protocols are still being established.
Clinical implications
For clinicians, the meta-analysis provides a stronger evidence base to support prescribing decisions. For patients, it offers hope that cannabis-based medicines may finally be taken more seriously as a treatment option for chronic pain.
